Rakeshkuma Patel, MD
Internal Medicine · Montgomery, ALNPI 1285625442
Payments from drug & device makers
Across 130 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$393
- AstraZeneca$353
- Pfizer$193
- GSK$187
- Lilly USA, LLC$166
- Johnson & Johnson$138
- plus $984 from 22 others
What the payments were for
- Food & beverage$2,29495%
- Gifts$1195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $393 |
| AstraZeneca | 21 | $353 |
| Pfizer | 11 | $193 |
| GSK | 10 | $187 |
| Lilly USA, LLC | 11 | $166 |
| Johnson & Johnson | 5 | $138 |
| Mannkind Corporation | 2 | $119 |
| Amgen(2 entities) | 5 | $95 |
| Abbott | 5 | $91 |
| Boehringer Ingelheim | 5 | $89 |
| E.r. Squibb & Sons, L.L.C. | 1 | $77 |
| Radius Health, Inc. | 3 | $77 |
| AbbVie | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Dexcom, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Bayer | 1 | $17 |
| Braemar Manufacturing, LLC | 1 | $14 |
| Novartis | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$2,413 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 205 | $247,223 |
| FarxigaDapagliflozin Propanediol | 196 | $198,982 |
| EliquisApixaban | 65 | $79,036 |
| OzempicSemaglutide | 52 | $59,945 |
| JanuviaSitagliptin Phosphate | 35 | $51,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $46,407 |
| JardianceEmpagliflozin | 37 | $45,741 |
| Xigduo XrDapaglifloz Propaned/Metformin | 42 | $45,087 |
| EntrestoSacubitril/Valsartan | 23 | $30,778 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $29,073 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $24,784 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $24,530 |
| KerendiaFinerenone | 16 | $21,501 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $20,948 |
| LinzessLinaclotide | 18 | $20,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $166 | $247,223205 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $353 | $226,850238 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $12 | $103,72993 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy | $89 | $85,01166 claims |
| PfizerEliquis | $193 | $79,03665 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $187 | $70,93768 claims |
| Novo NordiskOzempic | $393 | $59,94552 claims |
| NovartisEntresto | $14 | $30,77823 claims |
| AbbVieLinzess, Synthroid | $68 | $22,96543 claims |
| BayerKerendia | $17 | $21,50116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $17,91412 claims |
| Johnson & JohnsonXarelto | $138 | $14,24221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Montgomery
- John PorterMontgomery$316K
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.